Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Mr. Paul A. WilliamsSVP of Products Business | -694,00 | 5,55k | Sale to Issuer | 8,00 | 162,10k | -0,43% |
| 2026-06-08 | Mr. Richard S. LindahlExec. VP & CFO | -3,96k | 31,71k | Sale to Issuer | 8,00 | 113,48k | -3,38% |
| 2026-06-08 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -2,02k | 16,14k | Sale to Issuer | 8,00 | 202,20k | -0,99% |
| 2026-06-08 | Mr. William HartzelSVP of Manufacturing & Bioservices | -1,74k | 13,93k | Sale to Issuer | 8,00 | 185,56k | -0,93% |
| 2026-05-01 | Ms. Sujata T. DayalIndependent Director | -13,76k | 115,61k | Automatic Disposition | 8,36 - 8,94 | 100,56k | -12,04% |
| 2026-05-01 | Mr. Donald W. DeGolyerIndependent Director | -15,48k | 129,99k | Automatic Disposition | 8,36 - 8,96 | 129,72k | -10,66% |
| 2026-04-30 | Mr. Keith A. KatkinIndependent Director | -15,48k | 128,18k | Automatic Disposition | 8,28 | 96,29k | -13,85% |
| 2026-05-01 | Dr. Kathryn C. ZoonIndependent Director | -17,20k | 144,45k | Automatic Disposition | 8,36 - 8,97 | 79,94k | -17,71% |
| 2026-04-01 | Mr. Paul A. WilliamsSVP of Products Business | -4,00k | 33,76k | Automatic Disposition | 8,44 | 62,68k | -6,00% |
| 2025-05-07 | Mr. Richard S. LindahlExec. VP & CFO | -40,28k | 0,00 | Other Derivative Disposition | 48,33 - 61,01 | 0,00 | -100,00% |
| 2026-03-05 | Mr. Joseph C. PapaCEO, President & Director | -37,06k | 312,74k | Sale to Issuer | 8,44 | 305,45k | -10,82% |
| 2026-03-05 | Mr. Simon C. LowryChief Medical Officer and Head of Research & Development | -10,64k | 89,77k | Sale to Issuer | 8,44 | 16,48k | -39,22% |
| 2026-03-05 | Ms. Jessica PerlSenior VP, Corporate Secretary & General Counsel | -6,47k | 54,56k | Sale to Issuer | 8,44 | 61,00k | -9,58% |
| 2026-03-05 | Mr. William HartzelSVP of Manufacturing & Bioservices | -9,49k | 80,12k | Sale to Issuer | 8,44 | 87,19k | -9,82% |
| 2026-03-05 | Mr. Paul A. WilliamsSVP of Products Business | -9,40k | 79,31k | Sale to Issuer | 8,44 | 66,68k | -12,35% |
| 2026-03-05 | Mr. Richard S. LindahlExec. VP & CFO | -23,65k | 199,61k | Sale to Issuer | 8,44 | 215,37k | -9,89% |
| 2026-03-05 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -8,20k | 69,20k | Sale to Issuer | 8,44 | 104,11k | -7,30% |
| 2026-03-01 | Mr. Paul A. WilliamsSVP of Products Business | -116,00 | 945,40 | Sale to Issuer | 8,15 | 76,08k | -0,15% |
| 2026-03-01 | Mr. Richard S. LindahlExec. VP & CFO | -683,00 | 5,57k | Sale to Issuer | 8,15 | 239,02k | -0,28% |
| 2026-03-01 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -313,00 | 2,55k | Sale to Issuer | 8,15 | 112,31k | -0,28% |
| 2026-02-09 | Ms. Jessica PerlSenior VP, Corporate Secretary & General Counsel | -918,00 | 10,13k | Sale to Issuer | 11,03 | 67,47k | -1,34% |
| 2026-02-06 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -31,70k | 346,15k | Sale to Issuer | 10,92 | 112,62k | -21,96% |
| 2026-02-06 | Mr. William HartzelSVP of Manufacturing & Bioservices | -6,40k | 69,90k | Sale to Issuer | 10,92 | 96,68k | -6,21% |
| 2026-02-06 | Mr. Paul A. WilliamsSVP of Products Business | -9,68k | 105,67k | Sale to Issuer | 10,92 | 76,19k | -11,27% |
| 2026-02-06 | Mr. Richard S. LindahlExec. VP & CFO | -51,80k | 565,62k | Sale to Issuer | 10,92 | 239,70k | -17,77% |
| 2025-12-14 | Mr. Simon C. LowryChief Medical Officer and Head of Research & Development | -3,54k | 40,43k | Sale to Issuer | 11,41 | 6,28k | -36,05% |
| 2025-12-05 | Mr. Ronald B. RichardInsider | -25,75k | 177,09k | Derivative Exercise and Sale | 5,02 - 11,90 | 64,01k | - |
| 2025-12-05 | Mr. Ronald B. RichardInsider | -7,10k | 85,99k | Verkauf | 12,11 | 64,01k | -9,98% |
| 2025-11-11 | Mr. William HartzelSVP of Manufacturing & Bioservices | -610,00 | 6,64k | Sale to Issuer | 10,88 | 103,08k | -0,59% |
| 2025-11-10 | Mr. Donald W. DeGolyerIndependent Director | -17,80k | 187,62k | Automatic Disposition | 10,54 | 45,90k | -27,95% |
| 2025-11-07 | Ms. Sujata T. DayalIndependent Director | -8,55k | 85,52k | Automatic Disposition | 10,00 | 54,58k | -13,55% |
| 2025-10-15 | Mr. Richard S. LindahlExec. VP & CFO | -5,00k | 47,95k | Sale to Issuer | 9,60 | 291,50k | -1,68% |
| 2025-08-15 | Dr. Kathryn C. ZoonIndependent Director | -7,09k | 62,85k | Automatic Disposition | 8,87 | 37,40k | -15,93% |
| 2025-08-12 | Mr. Donald W. DeGolyerIndependent Director | -7,84k | 67,83k | Verkauf | 8,65 | 24,14k | -24,52% |
| 2025-07-11 | Mr. William HartzelSVP of Manufacturing & Bioservices | -4,26k | 31,38k | Sale to Issuer | 7,36 | 103,69k | -3,95% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
